ON123300

Cat. No.: 0225LY-0995

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: ON123300 acts as a multi-targeted and potent kinase inhibitor with IC50 values of 3.9 nM for CDK4, 5 nM for Ark5, 9.2 nM for RET, 11 nM for Fyn, and 26 nM for both FGFR1 and PDGFR-beta.

Synonym: 1357470-29-1; ON-123300; Narazaciclib; 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile; Pyrido(2,3-d)pyrimidine-6-carbonitrile, 8-cyclopentyl-7,8-dihydro-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-7-oxo-; 8-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)anilino]-7-oxopyrido[2,3-d]pyrimidine-6-carbonitrile

CAS No.: 1357470-29-1

Compound CID: 56649281

Formula: C₂₄H₂₇N₇

Formula Weight: 429.52

Specification

Targets&IC50: RET: 9.2nM; FGFR1: 26nM; CDK4: 3.9nM; Fyn: 11 nM; PDGFRβ: 26nM; Ark5: 5nM

Relative Density: 1.35 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: ON123300 can be used in oncology research to study the multi-kinase inhibition of CDK4 and ARK5.

Library Information

Target: JAK; Src; PDGFR; AMPK; FGFR; c-RET; CDK

Receptor: AMPK; Ark5; CDK; FGFR1; Fyn; PDGFRβ; RET

Pathways: JAK/STAT signaling; Angiogenesis; Chromatin/Epigenetic; Cell cycle/Checkpoint; Stem cell regulation; Apoptosis; Tyrosine kinase/adaptors; PI3K/Akt/mTOR signaling

Plate Number: AOCL-13

Plate Location: g8

Empty Location: a1-h1; a12-h12

Container: 96-well plate

DMSO Max Solubility: <1 mg/mL (insoluble or slightly soluble)

Water Max Solubility: <1 mg/mL (insoluble or slightly soluble)

Ethanol Max Solubility: <1 mg/mL (insoluble or slightly soluble)